Navigation Links
Drs. Ben Machielse Joins Omthera Pharmaceuticals, Inc. as Chief Operating Officer
Date:6/24/2011

BEDMINSTER, N.J., June 24, 2011 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that Drs. Ben Machielse has joined the Company as Executive Vice President and Chief Operating Officer, effective immediately.  In this newly created position, Drs. Machielse's responsibilities will include manufacturing, regulatory affairs, and quality and supply chain management.

Commenting on today's news, Jerry Wisler, President and Chief Executive Officer of Omthera, noted, "Ben brings to Omthera over 20 years of experience in all aspects of biopharmaceutical manufacturing, quality assurance, quality control and operations, and we are very pleased to welcome him into the key position of Chief Operating Officer. As our pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova™ progresses, it is critical that we continue to enhance our manufacturing and operational expertise and the robustness of our global supply chain for the anticipated  future commercial launch of Epanova, our novel, Omega-3 free fatty acid product.  Ben's deep experience in the biopharmaceutical industry will be invaluable as we navigate the next phase of the Company's development."

During his professional career, Drs. Machielse has been involved with the development and approval of seven biologic drugs.  Prior to joining Omthera, he spent 11 years with MedImmune, the last five as Executive Vice President Operations.  In that role, he led the worldwide manufacturing of therapeutic antibodies, small molecules and vaccine products – including the development and launch of the first H1N1 vaccine product available in the U.S.  He also oversaw quality assurance/quality control, GxP compliance, validation, supply chain, health and safety, and other functional areas.  Prior to his tenure with MedImmune, Drs. Machielse held the position of Vice President of Quality Assurance and Quality Control for Xoma, and before that, served in various positions in manufacturing, process and analytical development for Centocor BV.  Drs. Machielse received his Master of Science in biochemistry and Bachelor of Science in Medical Biology from the University of Utrecht, in Utrecht, The Netherlands.  He is a former member of the Board of Directors of Xencor and a current member of the Board of Directors for Tetragenetics.

"I am very pleased to be joining Omthera at such an exciting point in the Company's growth trajectory and was drawn to the position largely because of the tremendous potential represented by Epanova," noted Drs. Machielse. "Having demonstrated superior bioavailability compared to Lovaza® in a Phase II trial, Epanova may prove in Phase III trials to be as effective in lowering triglycerides as Lovaza® at a significantly lower dose, giving physicians the ability to titrate up for superior triglyceride lowering efficacy.  I am excited about this unique opportunity to help bring a potentially game changing drug to market and to create a new, best-in-class product.  As such, I am delighted to join Omthera's exceptional management team."

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia.  Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.  In March 2011, the Company initiated a pivotal Phase III clinical trial for its lead product candidate, Epanova™, an Omega-3 fatty acid compound in development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (greater than or equal to 500 mg/dL). Future planned clinical trials for Epanova include patients with high triglycerides (greater than or equal to 200 mg/dL and less than or equal to 500 mg/dL) currently on statin therapy.
For more information, please visit www.omthera.com.Omthera Contacts:Omthera Media Relations:Douglas Carr

Eric GoldmanFinancial Controller

Rx Communications GroupOmthera Pharmaceuticals

917-322-2563908-741-4323

egoldman@rxir.comDCarr@Omthera.com
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
2. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
3. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
4. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
5. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
6. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
11. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):